Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia

International Journal of Cancer

Volumn 137, Issue 12, 2015, Pages 2959-2970

  Opel, Daniela ^a   Schnaiter, Andrea ^a   Dodier, Dagmar ^a   Jovanovic, Marjana ^a   Gerhardinger, Andreas ^a   Idler, Irina ^a   Mertens, Daniel ^a   Bullinger, Lars ^a   Stilgenbauer, Stephan ^a   Fulda, Simone ^b,c  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

cell death; CLL; IAP proteins; Smac mimetic

Indexed keywords

ANTINEOPLASTIC AGENT; BV 6; CASPASE 3; CD40 LIGAND; CITRININ; ETANERCEPT; FLUDARABINE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; NAVITOCLAX; OBATOCLAX; PROTEIN P52; REACTIVE OXYGEN METABOLITE; RECEPTOR; RECEPTOR INTERACTING PROTEIN 1; STAUROSPORINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; BV6 PEPTIDE; OLIGOPEPTIDE; TNF PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UPREGULATION; ANTAGONISTS AND INHIBITORS; CELL DEATH; DRUG EFFECTS; DRUG SCREENING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MOLECULAR MIMICRY; PATHOLOGY; PROGNOSIS; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; CELL DEATH; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MOLECULAR MIMICRY; NF-KAPPA B; OLIGOPEPTIDES; PROGNOSIS; PROTEOLYSIS; REACTIVE OXYGEN SPECIES; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84943666249     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29650     Document Type: Article

References (53)

1. Hallek M, Cheson BD, Catovsky D, et al., International Workshop on Chronic Lymphocytic Leukemia Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-56
2. Zenz T, Mertens D, Kuppers R, et al., From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10: 37-50
3. Binet JL, Plunkett W, Robertson B, et al., What does apoptosis mean in CLL? Leuk Lymphoma 1996; 22 (Suppl 2): 47-52
4. Danilov AV, Danilova OV, Klein AK, et al., Molecular pathogenesis of chronic lymphocytic leukemia. Curr Mol Med 2006; 6: 665-75
5. Kolb JP, Kern C, Quiney C, et al., Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL. Curr Drug Targets Cardiovasc Haematol Disord 2003; 3: 261-86
6. Galluzzi L, Vitale I, Abrams JM, et al., Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012; 19: 107-20
7. Vandenabeele P, Galluzzi L, Vanden Berghe T, et al., Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010; 11: 700-14
8. Eckelman BP, Salvesen GS, Scott FL., Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 2006; 7: 988-94
9. Bertrand MJ, Milutinovic S, Dickson KM, et al., cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008; 30: 689-700
10. Liu Z, Sun C, Olejniczak ET, et al., Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 2000; 408: 1004-1008
11. Chen R, Plunkett W., Strategy to induce apoptosis and circumvent resistance in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2010; 23: 155-66
12. Grzybowska-Izydorczyk O, Cebula B, Robak T, et al., Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia. Eur J Cancer 2010; 46: 800-10
13. Loeder S, Zenz T, Schnaiter A, et al., A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. Cancer Res 2009; 69: 8977-86
14. Silva KL, Vasconcellos DV, Castro ED, et al., Apoptotic effect of fludarabine is independent of expression of IAPs in B-cell chronic lymphocytic leukemia. Apoptosis 2006; 11: 277-85
15. Fulda S, Vucic D., Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 2012; 11: 109-24
16. Varfolomeev E, Blankenship JW, Wayson SM, et al., IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007; 131: 669-81
17. Varfolomeev E, Vucic D., (Un)expected roles of c-IAPs in apoptotic and NFkappaB signaling pathways. Cell Cycle 2008; 7: 1511-21
18. Wu H, Tschopp J, Lin SC., Smac mimetics and TNFalpha: a dangerous liaison? Cell 2007; 131: 655-8
19. LaCasse EC, Mahoney DJ, Cheung HH, et al., IAP-targeted therapies for cancer. Oncogene 2008; 27: 6252-75
20. Dohner H, Stilgenbauer S, Benner A, et al., Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-16
21. Krober A, Bloehdorn J, Hafner S, et al., Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006; 24: 969-75
22. Zenz T, Krober A, Scherer K, et al., Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008; 112: 3322-9
23. Fulda S, Strauss G, Meyer E, et al., Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells. Blood 2000; 95: 301-8
24. Giagkousiklidis S, Vellanki SH, Debatin KM, et al., Sensitization of pancreatic carcinoma cells for gamma-irradiation-induced apoptosis by XIAP inhibition. Oncogene 2007; 26: 7006-16
25. Luck SC, Russ AC, Botzenhardt U, et al., Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroups. Leukemia 2011; 25: 1728-38
26. Luck SC, Russ AC, Du J, et al., KIT mutations confer a distinct gene expression signature in core binding factor leukaemia. Br J Haematol 2010; 148: 925-37
27. Eisen MB, Spellman PT, Brown PO, et al., Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863-8
28. Munk Pedersen I, Reed J., Microenvironmental interactions and survival of CLL B-cells. Leuk Lymphoma 2004; 45: 2365-72
29. Bhattacharya N, Reichenzeller M, Caudron-Herger M, et al., Loss of cooperativity of secreted CD40L and increased dose-response to IL4 on CLL cell viability correlates with enhanced activation of NF-kB and STAT6. Int J Cancer 2015; 136: 65-73
30. Wagner L, Marschall V, Karl S, et al., Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-kappaB-dependent manner. Oncogene 2013; 32: 988-97
31. Berger R, Jennewein C, Marschall V, et al., NF-kappaB is required for Smac mimetic-mediated sensitization of glioblastoma cells for gamma-irradiation-induced apoptosis. Mol Cancer Ther 2011; 10: 1867-75
32. Abhari BA, Cristofanon S, Kappler R, et al., RIP1 is required for IAP inhibitor-mediated sensitization for TRAIL-induced apoptosis via a RIP1/FADD/caspase-8 cell death complex. Oncogene 2013; 32: 3263-73
33. Eckhardt I, Roesler S, Fulda S., Identification of DR5 as a critical, NF-kappaB-regulated mediator of Smac-induced apoptosis. Cell Death Dis 2013; 4: e936
34. Eckhardt I, Weigert A, Fulda S., Identification of IRF1 as critical dual regulator of Smac mimetic-induced apoptosis and inflammatory cytokine response. Cell Death Dis 2014; 5: e1562
35. Vince JE, Wong WW, Khan N, et al., IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007; 131: 682-93
36. Petersen SL, Wang L, Yalcin-Chin A, et al., Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007; 12: 445-56
37. Oberst A, Green DR., It cuts both ways: reconciling the dual roles of caspase 8 in cell death and survival. Nat Rev Mol Cell Biol 2011; 12: 757-63
38. Vandenabeele P, Declercq W, Vanden Berghe T., Necrotic cell death and 'necrostatins': now we can control cellular explosion. Trends Biochem Sci 2008; 33: 352-5
39. Maas C, Tromp JM, van Laar J, et al., CLL cells are resistant to smac mimetics because of an inability to form a ripoptosome complex. Cell Death Dis 2013; 4: e782
40. Scavullo C, Servida F, Lecis D, et al., Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL). Leuk Res 2013; 37: 809-15
41. Frenzel LP, Patz M, Pallasch CP, et al., Novel X-linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis. Br J Haematol 2011; 152: 191-200
42. Trachootham D, Alexandre J, Huang P., Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009; 8: 579-91
43. Sablina AA, Budanov AV, Ilyinskaya GV, et al., The antioxidant function of the p53 tumor suppressor. Nat Med 2005; 11: 1306-13
44. Varfolomeev E, Goncharov T, Fedorova AV, et al., cIAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem 2008; 283: 24295-9
45. Belz K, Schoeneberger H, Wehner S, et al., Smac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assembly. Blood 2014; 124: 240-50
46. Stadel D, Cristofanon S, Abhari BA, et al., Requirement of nuclear factor kappaB for Smac mimetic-mediated sensitization of pancreatic carcinoma cells for gemcitabine-induced apoptosis. Neoplasia 2011; 13: 1162-70
47. Steinhart L, Belz K, Fulda S., Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis. Cell Death Dis 2013; 4: e802
48. Li W, Li B, Giacalone NJ, et al., BV6, an IAP antagonist, activates apoptosis and enhances radiosensitization of non-small cell lung carcinoma in vitro. J Thorac Oncol 2011; 6: 1801-9
49. Vellanki SH, Grabrucker A, Liebau S, et al., Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma. Neoplasia 2009; 11: 743-52
50. Fulda S, Galluzzi L, Kroemer G., Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 2010; 9: 447-64
51. Chauhan D, Neri P, Velankar M, et al., Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood 2007; 109: 1220-7
52. Gaither A, Porter D, Yao Y, et al., A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Res 2007; 67: 11493-8
53. Krepler C, Chunduru SK, Halloran MB, et al., The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Clin Cancer Res 2013; 19: 1784-94